Drug Trial Radar · NCT02366884
Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
Last checked: Nov 20, 2026Latest source record: Apr 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
250
Planned (sponsor's estimate)
Start
Jul 26, 2011
Primary completion
Dec 31, 2022
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Dr. Frank Arguello Cancer ClinicIndustry
- Sponsor type
- Industry
- Collaborators
- Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com
- First posted
- Feb 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The cell behavior that the investigators regard as "malignant," including: cell autonomy; invasion and digestion of surrounding normal tissues; migration and colonization of distant organs; ability to develop resistance to drugs, temperature, or radiation; and ability to kill the host, are not only characteristics of cancer cells, but of pathogenic and/or opportunistic unicellular organisms (bacteria, fungi and protozoa). Rudolf Virchow (1821-1902), the father of modern pathology, first pointed out the resemblance between the biological behavior of cancer cells and that of single-celled organisms when causing infections. He thought, incorrectly, that cancer cells were cells infected with bacteria and had acquired their pathogenic behavior from them. Others later postulated that the behavior of cancer cells was likely due to the re-expression of past traits and behaviors (atavism) derived from their past evolutionary experience as independent, single-celled organisms from which all cells in multicellular organisms originated. In other words, the behavior of pathogenic unicellular organisms, including: unlimited replicative potential; capacity for invasion, migration, and metastases; abilities to evade the host's immune system, to generate multi-drug resistance; and to kill a host, are what the investigators define as "cancer" when one of the investigators cells re-express these past ancestral traits. This reversion or de-evolution of a differentiated cell to its ancestral undifferentiated, unicellular form has been named "Atavistic Metamorphosis." This does not imply that cancer cells are bacteria, protozoa, or yeasts. It means that cancer cells express functions and/or behaviors similar to their ancestral parents, the unicellular organisms from which our cells originated. If this is true, a combination of drugs that are effective to eradicate certain unicellular organisms may work in cancer treatment. The principal objective of this study is to determine whether there is a benefit for patients with advanced, metastatic and terminal cancers to be treated with combinations of selected drugs conventionally used in medical practice to kill bacterial, fungal and protozoal cells.
Conditions
- Neoplasms
Interventions
Anti-Bacterial AgentsDrug
Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
Anti-Fungal AgentsDrug
Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
Anti-Protozoal AgentsDrug
Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical efficacy as measured by the number of participants with an objective clinical tumor regression responseTime frame: 6 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dr. Frank Arguello Cancer Clinic
San José del Cabo, Baja California Sur, Mexico · Recruiting
Instituto de Ciencia y Medicina Genomica
Torreón, Coahuila, Mexico · Enrolling by invitation
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.